Nicola Dalbeth

Nicola Dalbeth is a New Zealand rheumatology academic. She is a full professor at the University of Auckland.[1]

Nicola Dalbeth
Alma materUniversity of Otago
Scientific career
InstitutionsUniversity of Auckland

Academic career

After earning a medical degree at the University of Otago, and training at Oxford University and Imperial College London she moved to the University of Auckland, rising to full professor.[1][2] In 2019, Dalbeth was elected a Fellow of the Royal Society of New Zealand.[3]

Much of Dalbeth's research focuses on gout, a chronic disease of monosodium urate crystal deposition.[4]

Selected works
  • Khanna, Dinesh, John D. Fitzgerald, Puja P. Khanna, Sangmee Bae, Manjit K. Singh, Tuhina Neogi, Michael H. Pillinger et al. "2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia." Arthritis care & research 64, no. 10 (2012): 1431-1446.
  • Khanna, Dinesh, Puja P. Khanna, John D. Fitzgerald, Manjit K. Singh, Sangmee Bae, Tuhina Neogi, Michael H. Pillinger et al. "2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis." Arthritis care & research 64, no. 10 (2012): 1447-1461.
  • Neogi, Tuhina, Tim L. Th A. Jansen, Nicola Dalbeth, Jaap Fransen, H. Ralph Schumacher, Dianne Berendsen, Melanie Brown et al. "2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative." Arthritis & rheumatology 67, no. 10 (2015): 2557-2568.
  • Dalbeth, Nicola, Roger Gundle, Robert JO Davies, YC Gary Lee, Andrew J. McMichael, and Margaret FC Callan. "CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation." The Journal of Immunology 173, no. 10 (2004): 6418-6426.
  • Dalbeth, Nicola, Sunil Kumar, Lisa Stamp, and Peter Gow. "Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout." The Journal of Rheumatology 33, no. 8 (2006): 1646-1650.
gollark: He doesn't understand some things, which is fine I guess, but he also doesn't seem to understand the things he needs to understand to understand those things either, and seems to think he's done with things when the arbitrary computer marking thing™ says so even when it's repeatedly blatantly wrong, and wants me to just give him answers so he'll apparently learn from them.
gollark: Trying to explain "algebraic proof" to Zachary is so intensely frustrating.
gollark: I don't think that's right either.
gollark: Really?
gollark: Not interesting.

References
  1. "Professor Nicola Dalbeth - The University of Auckland". unidirectory.auckland.ac.nz.
  2. "Dr Nicola Dalbeth • Healthpoint". www.healthpoint.co.nz.
  3. "Researchers and scholars at the top of their fields elected as Fellows". Royal Society Te Apārangi. 21 November 2019. Retrieved 27 November 2019.
  4. "Nicola Dalbeth and Keith J Petrie: It's time to change the name of gout - The BMJ". 5 February 2018.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.